Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMicrosaic Regulatory News (MSYS)

Share Price Information for Microsaic (MSYS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.05
Bid: 1.00
Ask: 1.10
Change: 0.00 (0.00%)
Spread: 0.10 (10.00%)
Open: 1.05
High: 1.05
Low: 1.05
Prev. Close: 1.05
MSYS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Development of PFAS detection platform

25 May 2021 07:00

RNS Number : 6528Z
Microsaic Systems plc
25 May 2021
 

Reach

 

25 May 2021

Microsaic Systems plc

("Microsaic" or the "Company")

Joint development of 'Forever Chemicals' detection platform with Swansea University and Investor Presentation

Microsaic equipment used for environmental monitoring, to inform the links between environmental pollution and public health.

Microsaic (AIM: MSYS), the developer of point of need mass spectrometry ("MS") instruments, is delighted to announce a collaboration with Swansea University Medical School, utilising Microsaic's miniature mass spectrometry equipment, to develop a monitoring platform capable of measuring per- and polyfluoroalkyl substances ("PFAS", also known as 'forever chemicals') at source and within a laboratory setting. This will be used to establish the health impacts of the broader range of PFAS pollutants. The detection platform will combine environmental sample preparation and epigenetic approaches with Microsaic's miniature mass spectrometer. Through partnership with stakeholders in the environmental sector, this collaboration is designed to better inform pollution remediation, improve management processes for reduced emission and promote safer handling of PFAS chemicals.

 

PFAS are pollutants of increasing concern, known as 'forever chemicals' given their environmental persistence following use as protective, non-stick and fire-retardant coatings within electronics, textiles, cleaning agents and cookware1. There is a shortage of environmental testing globally yet initial human epigenetic studies show reproductive, developmental, liver, kidney, and immunological effects1,2,3 from skin contact or contaminated food or water, meaning there is an increasing need to monitor these pollutants. Furthermore, given there are conflicting accounts of the epigenetic mechanisms of specific PFAS (e.g. DNA methylation with PFOS and PFOA)3,4, questions remain as to how epigenetic changes occur across the chemical breadth and for mixtures of PFAS pollutants.

 

Environmental pollution has been strongly linked to adverse human health outcomes, prompting growing research activity to determine how this leads to disease. Given the breadth of chemicals used in everyday life and their resistance to environmental breakdown, the risk of pollution following release via production, use, ineffective wastewater remediation, and/or leachate from landfill is significant.

 

Glenn Tracey, CEO of Microsaic Systems plc, commented:

"Establishing 'Fit-for-purpose' monitoring approaches is critical to understanding better which pollutants are present, the degree of exposure to and risk posed by such pollutants, and efficacy of management processes to control how they are released and to mitigate harm better. Current monitoring approaches typically require individual sample collection onsite, with sample preparation and analysis using complex instrumentation in a remote laboratory, resulting in delayed deployment of mitigation measures.

 

We believe that the world needs remote monitoring solutions that provide real-time data of chemical pollution, to inform automated or other process management or clean-up processes, for reduced environmental and public health impact.

 

I am delighted that Microsaic's point of need technology are being used in this effort to drive improvements in online environmental monitoring and ground-breaking research to help inform the links between environmental pollutants and their effects on the human genome."

 

Investor Presentation

 

Microsaic is pleased to announce that Glenn Tracy, CEO of the Company, will provide a live presentation relating to the development of the 'Forever Chemicals' detection platform with Swansea University via the Investor Meet Company platform on 27 May 2021 at 4:30pm BST.

 

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 9:00am the day before the meeting or at any time during the live presentation.

 

Investors can sign up to Investor Meet Company for free and add to meet Microsaic Systems plc via:

https://www.investormeetcompany.com/microsaic-systems-plc/register-investor 

Investors who already follow Microsaic Systems plc on the Investor Meet Company platform will automatically be invited.

 

References:

1EPA, https://www.epa.gov/pfas/basic-information-pfas#difference

2Toxicology Department CRCE, PHE 2009 Version 1 , PFOS and PFOA: General Information

3Kim, S,., Thapar, I., Brooks, B. W., Epigenetic changes by per- and polyfluoroalkyl substances (PFAS). 2021. Env. Pol. 279: p. 116929.

4Kingsley, S.L., Kelsey, K.T., Butler, R., Chen, A., Eliot, M.N., Romano, M.E., et al., 2017. Maternal serum PFOA concentration and DNA methylation in cord blood: a pilot study. Environ. Res. 158, 174e178. etc

 

Enquiries:

 

Microsaic Systems plc

Glenn Tracey, CEO

Bevan Metcalf, FD

+44 (0)1483 751 577

 

 

N+1 Singer (Nominated Adviser & Joint Broker)

+44 (0)20 7496 3000

Aubrey Powell / George Tzimas (Corporate Finance)

 

Tom Salvesen (Corporate Broking) 

 

 

 

Turner Pope Investments (TPI) Limited (Joint Broker)

James Pope

+44 (0) 20 3657 0050

 

 

About Microsaic (www.microsaic.com)

Microsaic listed on AIM in 2011 to develop and commercialise micro-engineering chip-based mass spectrometry equipment. Having invested £30m over the last 20 years before and after the IPO, Microsaic has a robust patent portfolio in cutting-edge technology purpose built for "Industry 4.0" which enables analytical detection and characterisation at the point-of-need, whether within a human health environment, conventional laboratory setting, or within a bioprocessing facility for continuous mass spectrometer detection and monitoring of data at any step in the process workflow.

Microsaic's products and systems are commercially available through global markets via a network of regional and local partners, targeting its core laboratory, manufacturing and point-of-need applications. 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAVZLFLFELZBBL
Date   Source Headline
5th Mar 20197:00 amRNSInvestor Event
19th Feb 20197:00 amRNSNotice of Results
11th Jan 20197:00 amRNSNew Protein Identification Product
19th Dec 201811:20 amRNSBioprocessing partnership update & trading update
7th Nov 20187:00 amRNSExclusive US and Canada Distribution Agreement
3rd Sep 20187:00 amRNSInterim Results
7th Aug 20187:00 amRNSNotice of Results
29th Jun 20184:12 pmRNSHolding(s) in Company
26th Jun 20182:04 pmRNSHolding(s) in Company
25th Jun 201810:10 amRNSDirectors' Interests
22nd Jun 201810:40 amRNSResult of GM, Completion of Fundraising & TVR
21st Jun 20187:00 amRNSDistribution Agreement with Amedis, spol. s ro.
13th Jun 20187:00 amRNSDistribution Agreement with Omicron Research Ltd.
6th Jun 20187:00 amRNSSuccessful Fundraising of £5.5 million
5th Jun 20184:46 pmRNSPrimaryBid.com Offer
5th Jun 20184:45 pmRNSFundraising
24th May 20187:00 amRNSDistribution Agreement with Stable Arm Sdn. Bhd.
9th May 20187:00 amRNSAgreement with Rightek Co., Ltd.
4th May 201811:25 amRNSResult of AGM
4th May 20187:00 amRNSAGM Statement
12th Apr 20187:00 amRNSMicrosaic signs Agreement with Knauer
6th Apr 20187:00 amRNSNotice of AGM and Posting of Annual Report
28th Mar 20187:00 amRNSAgreement with Unimicro Technologies Inc.
23rd Mar 20184:45 pmRNSHolding(s) in Company
21st Mar 20187:00 amRNSCommercial contract with CPI Innovation Services
5th Mar 20187:00 amRNSFinal Results
21st Feb 20187:00 amRNSNotice of Results
3rd Jan 20187:00 amRNSAward of Options
19th Dec 20177:00 amRNSDirectorate Change
13th Dec 20177:00 amRNSResearch agreement with global biopharma partner
28th Sep 20177:00 amRNSInterim Results
25th Sep 20177:00 amRNSAppointment of CEO
13th Sep 20177:00 amRNSMicrosaic to Exhibit at BioProcess International
14th Aug 20177:00 amRNSNotice of Results
19th Jun 20177:00 amRNSTrading Statement
15th May 201711:42 amRNSResult of AGM
11th May 20177:00 amRNSMicrosaic Enhances Bioprocessing Capabilities
26th Apr 20177:00 amRNSIntegration with SCPA chromatography software
21st Apr 20177:00 amRNSNotice of AGM
7th Apr 20177:00 amRNSAgreement
21st Mar 20177:00 amRNSFinal Results
13th Mar 20177:00 amRNSChange of registrar
24th Jan 201712:56 pmRNSAppointment of Interim Chairman
13th Dec 20167:00 amRNSTrading Statement
28th Sep 20167:00 amRNSDirectorate Change
21st Sep 20164:39 pmRNSHolding(s) in Company
16th Sep 20161:44 pmRNSDirector/PDMR Shareholding
15th Sep 20161:03 pmRNSHolding(s) in Company
15th Sep 201610:02 amRNSTR-1: Notification of Major Interest in Shares
14th Sep 20165:23 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.